BAX Q3 Deep Dive: Mixed Segment Results and Lowered Guidance Drive Market Reaction
Update: 2025-10-31
Description
Baxter International's Q3 earnings report was a mixed bag, with sales increasing by 5% but missing Wall Street's expectations. The company's forecast for the next quarter was also disappointing, with a guidance of $2.81 billion. However, Baxter beat estimates on profit per share, reporting $0.69. The company's Infusion Therapies and Technologies division faced ongoing issues, while the Healthcare Systems and Technologies segment showed resilience. Baxter's stock dropped after the earnings news, and the company announced a significant dividend cut to focus on debt repayment. The company expects challenges to persist, including a hold on Novum IQ pump shipments and underwhelming demand for IV solutions. Baxter's next steps will be closely watched as investors look for signs of cost reductions and improvements in key business lines.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
